1. Home
  2. PRAX vs CHE Comparison

PRAX vs CHE Comparison

Compare PRAX & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$322.54

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

CHE

Chemed Corp

HOLD

Current Price

$487.70

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
CHE
Founded
2015
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.1B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
PRAX
CHE
Price
$322.54
$487.70
Analyst Decision
Strong Buy
Buy
Analyst Count
15
4
Target Price
$572.13
$501.50
AVG Volume (30 Days)
548.0K
191.7K
Earning Date
05-08-2026
04-23-2026
Dividend Yield
N/A
0.57%
EPS Growth
N/A
N/A
EPS
N/A
4.84
Revenue
N/A
$2,529,978,000.00
Revenue This Year
N/A
$6.56
Revenue Next Year
$7,758.26
$6.23
P/E Ratio
N/A
$101.37
Revenue Growth
N/A
4.06
52 Week Low
$37.25
$365.21
52 Week High
$366.52
$492.30

Technical Indicators

Market Signals
Indicator
PRAX
CHE
Relative Strength Index (RSI) 54.07 67.71
Support Level $282.49 $418.47
Resistance Level $344.07 N/A
Average True Range (ATR) 21.29 11.23
MACD 2.92 2.76
Stochastic Oscillator 54.65 89.63

Price Performance

Historical Comparison
PRAX
CHE

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About CHE Chemed Corp

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Share on Social Networks: